HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antihistamine OTC Switch Petition Slated For NDAC Debate May 11

This article was originally published in The Tan Sheet

Executive Summary

FDA's decision to bring a citizen petition seeking OTC status of three low- and non-sedating antihistamine drugs before NDAC may be an attempt to apply public pressure on Schering-Plough, Aventis and Pfizer to accelerate any plans they may have to initiate switches on their own.

You may also be interested in...



Switch Petitions Must Come From NDA Holders, CHPA Says

Drug manufacturers, with the guidance of FDA, are the only qualified parties to gather the data necessary to establish that a drug can be safely used without a prescription, the Consumer Healthcare Products Association asserts.

New Rx Antihistamines Free From Cardio Risks Of Predecessors - JAPhA

Newer second-generation antihistamines are safer than older Rx drugs discontinued for safety reasons, a commentary in the May/June Journal of the American Pharmaceutical Association asserts.

Antihistamine OTC Switch: FDA Asking If Rx Products Have "Unique" Aspects

FDA regards the safety profiles of Rx antihistamines Claritin, Allegra and Zyrtec to be at least as good as currently marketed OTC antihistamines, briefing documents for the upcoming May 11 advisory committee meeting indicate.

Related Content

Topics

UsernamePublicRestriction

Register

RS132547

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel